P1.15-15 Real-World Experience With Afatinib After Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.947
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance

British Journal of Cancer
Cancer ResearchOncology
2019English

The Association of Acquired T790M Mutation With Clinical Characteristics After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Cancer Research and Treatment
Cancer ResearchOncology
2018English

Impact of Epidermal Growth Factor Receptor Gene Expression Level on Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Patients Taking First-Line Epidermal Growth Factor Receptor–tyrosine Kinase Inhibitors

Tumor Biology
MedicineCancer Research
2017English

P1.01-36 Thoracic Surgery in Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Early Radiographic Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations: A Prospective Study

Biomedical Journal
Medicine
2015English

Association of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment and EGFR Exon 19 Deletion With Frequency of the T790M Mutation in Non-Small Cell Lung Cancer Patients After Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

OncoTargets and Therapy
OncologyPharmacology
2019English

Nucleotide Binding by the Epidermal Growth Factor Receptor Protein-Tyrosine Kinase

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1996English

Lung Cancer Cells Survive Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Exposure Through Upregulation of Cholesterol Synthesis

FASEB BioAdvances
2019English

Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma

Oncology Letters
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy